AOD-9604 vs MOTS-c: Which Is Better?

Creator: FormBlends Medical Team
Published: 2025-12-19

AOD-9604 vs MOTS-c comparison. Fat-loss peptide vs Mitochondrial-derived peptide. When to use each and how they differ.

By FormBlends Editorial Research|Source reviewed by FormBlends Medical Team|Last reviewed April 1, 2026|Published December 19, 2025

Source Reviewed

Written by FormBlends Editorial Research · Checked against primary sources by FormBlends Medical Team

Custom header image for AOD-9604 vs MOTS-c: Which Is Better?, Peptide Therapy, and better treatment decision-making.

In This Article

This article is part of our Peptide Therapy collection. See also: GLP-1 Guides | Provider Comparisons

Search and AI answer brief

Practical answer: AOD-9604 vs MOTS-c: Which Is Better?

AOD-9604 vs MOTS-c comparison. Fat-loss peptide vs Mitochondrial-derived peptide. When to use each and how they differ.

Short answer

AOD-9604 vs MOTS-c comparison. Fat-loss peptide vs Mitochondrial-derived peptide. When to use each and how they differ.

Search intent

This page answers a specific Peptide Therapy question rather than a generic overview.

What to verify

peptide evidence quality

How to use it

Use this information to prepare sharper questions for a licensed provider.

Key Takeaway

Researching AOD-9604? See it at FormBlends →

AOD-9604 vs MOTS-c comparison. Fat-loss peptide vs Mitochondrial-derived peptide. When to use each and how they differ.

Quick Answer: AOD-9604 vs MOTS-c compares a fat-loss peptide with a mitochondrial-derived peptide. AOD-9604 is used for lipolysis stimulation. MOTS-c is used for metabolic improvement, exercise enhancement. These compounds serve different purposes and your choice depends on your primary health goal. They can often be used together since they work through independent mechanisms .

Head-to-Head Comparison

AOD-9604 vs MOTS-c
Factor	AOD-9604	MOTS-c
Category	Fat-loss peptide	Mitochondrial-derived peptide
Primary role	Lipolysis stimulation	Metabolic improvement, exercise enhancement
Mechanism	GH fragment-mediated fat oxidation	AMPK activation, glucose metabolism regulation
Best for	Stubborn fat reduction, body composition	Insulin sensitivity, exercise capacity, metabolic health
Administration	SC injection daily	SC injection
Evidence	Preclinical + limited clinical	Emerging preclinical + early clinical

When to Choose AOD-9604

Stubborn fat reduction is your primary goal
You want lipolysis stimulation
Stubborn fat reduction, body composition are your focus areas

When to Choose MOTS-c

Insulin sensitivity is your primary goal
You want metabolic improvement, exercise enhancement
Insulin sensitivity, exercise capacity, metabolic health are your focus areas

Can You Use Both?

Yes. AOD-9604 and MOTS-c work through independent mechanisms and don't interfere with each other. They can be combined when your health goals span both lipolysis stimulation and metabolic improvement. Your physician can design a protocol that incorporates both compounds with appropriate timing and dosing.

From the FormBlends catalog

AOD-9604

Fat-targeting fragment without growth hormone side effects · From $199/mo · compounded by a licensed 503A pharmacy, dispensed only after provider review.

View AOD-9604 →

Popular Therapeutic Peptides by Use Case. Based on published peptide research literature.

View data table

Bar chart showing popular therapeutic peptides by use case: BPC-157 (88), TB-500 (82), Sermorelin (78), Ipamorelin (75), GHK-Cu (70)
Category	Clinical Interest Score	Detail
BPC-157	88	Tissue repair and gut healing
TB-500	82	Injury recovery
Sermorelin	78	Growth hormone support
Ipamorelin	75	Anti-aging and recovery
GHK-Cu	70	Skin and tissue repair

Frequently Asked Questions

Which has stronger evidence?

AOD-9604 has preclinical + limited clinical. MOTS-c has emerging preclinical + early clinical. The strength of evidence depends on the specific application you're considering.

Which should I start with?

Start with whichever addresses your most pressing health concern. If you need lipolysis stimulation, start with AOD-9604. If you need metabolic improvement, start with MOTS-c. A physician can help you prioritize.

Find Your Optimal Protocol

At FormBlends, our physicians evaluate your health goals and recommend the most effective approach, whether single compounds or strategic combinations.

Schedule Your Free Consultation

Disclaimer: This article is for informational purposes only and doesn't constitute medical advice. Always consult with a licensed healthcare provider. Individual results may vary.

Ready when you are

AOD-9604

Fat-targeting fragment without growth hormone side effects · From $199/mo · compounded by a licensed 503A pharmacy, dispensed only after provider review.

View AOD-9604 →

Browse the full catalog →

Research Snapshot

Head-to-head comparison

Entities covered

FormBlends

Page type

Head-to-head comparison

FormBlends review

Last reviewed

2026-04-01

FormBlends review

FormBlends official source

formblends.com

Official source

Before you buy

Confirm current pricing, medication availability, pharmacy sourcing, and cancellation terms directly with the provider.

Check before ordering

Provider pricing, medication availability, pharmacy partners, insurance support, and cancellation rules can change quickly. This snapshot is designed to make verification easier, not to replace checking the official source before making a medical or purchase decision. Last page review: 2026-04-01.

Evidence standard

How this page was source-checked

Editorial policy

FormBlends does not claim an individual clinician byline unless a named reviewer is available. For this page, the editorial team checks medical and regulatory claims against primary sources, clinical trials, public datasets, and regulator guidance.

FDA category lists for bulk drug substances

Regulator

Used to distinguish studied peptides from peptides that lack lawful compounding status.

ClinicalTrials.gov

Dataset

Used to separate human trial evidence from animal, mechanistic, or anecdotal claims.

PubMed evidence trail

Research sources used to frame this page

For AOD-9604 vs MOTS-c: Which Is Better?, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

ReviewMOTS-c and mitochondrial peptide evidence2015

The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance

Foundational preclinical study (Cell Metabolism) where MOTS-c prevented diet-induced obesity and insulin resistance in mice; no human data.

PubMed

ReviewMOTS-c and mitochondrial peptide evidence2016

MOTS-c: A novel mitochondrial-derived peptide regulating muscle and fat metabolism

Review summarizing MOTS-c metabolic effects drawn from rodent and cell studies, not human trials.

PubMed

ReviewMOTS-c and mitochondrial peptide evidence2024

Correlation between mitochondrial-derived peptide (MDP) levels and metabolic states: a systematic review and meta-analysis

Pooled observational human studies of circulating MDP levels across metabolic states; the evidence is correlational, not interventional.

PubMed

ReviewAOD-9604 evidence2001

Effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism in obese and beta3-AR knockout mice

Mouse study; AOD9604 affected fat metabolism in mice, but the subsequent human obesity efficacy trial reported no meaningful weight loss versus placebo.

PubMed

ReviewAOD-9604 evidence2001

Increase of fat oxidation and weight loss in obese mice by a modified C-terminal GH fragment

Obese-mouse study of the AOD9604 fragment; preclinical only, and these effects were not reproduced in human obesity trials.

PubMed

ReviewAOD-9604 evidence2005

Gateways to clinical trials

Drug-pipeline review listing AOD-9604 in clinical development; it was later dropped after human obesity trials failed to show clinically meaningful weight loss.

PubMed

ReviewNAD+ and precursor evidence2021

NAD+ metabolism and its roles in cellular processes during ageing

Core review for NAD+ decline, mitochondrial function, DNA repair, and aging biology.

PubMed

Randomized trialNAD+ and precursor evidence2021

Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women

Human NMN source for metabolic claims while keeping population limits clear.

PubMed

Randomized trialNAD+ and precursor evidence2018

Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults

Human NR source for NAD+ level and tolerability discussions.

PubMed

Comparison decision path

Use this comparison to narrow the provider review question

Direct answer

AOD-9604 vs MOTS-c: Which Is Better? should help you decide which option deserves a clinical review, not force a one-size answer.

Start the provider review

Evidence check

A strong comparison should connect mechanism, evidence strength, safety, access, and cost instead of only naming a winner.

Safety check

The right choice can change based on history, medication interactions, side effects, budget, and availability.

Next step

After comparing, use the get-started flow to route your goals and health history into the right prescription review path.

Helpful context before the funnel

All comparisons

Compare nearby medications, providers, and treatment paths.

Product options

Move from comparison to treatment fit.

Cost calculator

Check whether the practical path matches your budget.

FormBlends Editorial Context

Reviewed May 14, 2026

AOD-9604 vs MOTS-c comparison. Fat-loss peptide vs Mitochondrial-derived peptide. When to use each and how they differ. Treat "AOD-9604 vs MOTS-c: Which Is Better?" as a way to pressure-test a decision before money, medication, or provider access is involved. The article ties the main claim, safety boundary, and next practical step back to comparison and decision support. It belongs in a peptide therapy guide where research status, sourcing, compounding quality, dosing, and clinician oversight all need extra scrutiny. Because this article has 6 major sections, scan the headings first and then use the FAQ or summary sections to pressure-test the answer. Keep the final call tied to your own labs, history, medications, and clinician guidance.

Confirm whether the page is discussing an FDA-approved use, a compounded option, or research-only context.
Ask a licensed clinician how the evidence applies to your health history, medications, labs, and side-effect risk.
Check the latest label, trial update, pharmacy policy, or state rule when the article touches medication access.

Original tools and data

Use the FormBlends research stack

These assets are built to be useful beyond a single article: shareable data pages, calculators, provider comparisons, and safety checks that give Google and readers something original to crawl.

2026 GLP-1 Telehealth Report

105 providers scored on price, safety, compliance, and patient experience.

Compounded GLP-1 ZIP Lookup

State pharmacy-board posture and telehealth access for US ZIP codes.

America on GLP-1 Map

County-level adoption estimates using CDC, Census, and KFF inputs.

Editorial refresh

Practical 2026 note for AOD

This update makes AOD more specific by tying BPC-157, aod, 9604, mots, which, better to the page's original clinical, cost, access, or comparison angle.

The goal is to make the article more useful for people who already know the headline question and need page-level specifics, not another interchangeable peptide therapy summary.

For 2026 review, the content emphasizes current verification, treatment fit, and patient-safety questions that can be discussed with a qualified provider.

AOD custom 2026 image for peptide therapy on FormBlends — Image description: Unique image for this page covering AOD, peptide therapy, safety, cost, provider selection, and patient decision-making.

Download the Peptide Quick Reference Card

A printable 2-page reference covering popular peptides, dosing ranges, stacking protocols, and storage.

Free download. We'll also send helpful GLP-1 guides to your inbox. Unsubscribe anytime.

Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication or treatment. FormBlends articles are source-checked against medical and regulatory references, but they are not a substitute for a personal medical consultation.

Written by FormBlends Editorial Research

Prepared by FormBlends Editorial Research. Claims are checked against primary regulatory, trial, label, and public-health sources where available. Reviewed by FormBlends Medical Team for medical accuracy, sourcing, and patient-safety framing.

AOD-9604 vs MOTS-c: Which Is Better?

Practical answer: AOD-9604 vs MOTS-c: Which Is Better?

Head-to-Head Comparison

When to Choose AOD-9604

When to Choose MOTS-c

Can You Use Both?

Frequently Asked Questions

Which has stronger evidence?

Which should I start with?

Find Your Optimal Protocol

Research Snapshot

How this page was source-checked

Research sources used to frame this page

Use this comparison to narrow the provider review question

FormBlends Editorial Context

Use the FormBlends research stack

Practical 2026 note for AOD

Download the Peptide Quick Reference Card

Ready to Start Your Weight Loss Journey?

Next Best Reads

BPC-157 vs MOTS-c: Which Is Better?

CJC-1295 vs MOTS-c: Which Is Better?

GHK-Cu vs MOTS-c: Which Is Better?

Glutathione vs MOTS-c: Which Is Better?

Ipamorelin vs MOTS-c: Which Is Better?

MOTS-c vs Epithalon: Which Is Better?

Free Tools

BMI Calculator

Cost Calculator

Drug Interaction Checker

Dosing Schedule

Helpful Content